Skip to content

Pharminent

Primary Menu
  • Home
    • Signal News
Light/Dark Button
Brief
  • Home
  • Regulatory
  • BMS secures FDA acceptance for Camzyos sNDA
  • Regulatory

BMS secures FDA acceptance for Camzyos sNDA

Pharmaceutical Business Review

The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026.

Cardiovascular

Read full story

pharminent June 2, 2026 (Last updated: June 4, 2026)

Pharmaceutical Business Review

The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026.

Cardiovascular

Read full story

Post navigation

Previous: Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
Next: Deep Science Ventures and MDC partner to accelerate brain treatments

Related Stories

  • Regulatory

FDA clears Takeda, Protagonist’s first-in-class PV drug

pharminent August 31, 2026
  • Regulatory

FDA green lights Priovant drug for rare skin disease

pharminent August 28, 2026
  • Regulatory

Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2

pharminent August 26, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.